TY - JOUR
T1 - Alzheimer Disease Biomarkers and Driving in Clinically Normal Older Adults
AU - Allison, Samantha
AU - Babulal, Ganesh M.
AU - Stout, Sarah H.
AU - Barco, Peggy P.
AU - Carr, David B.
AU - Fagan, Anne M.
AU - Morris, John C.
AU - Roe, Catherine M.
AU - Head, Denise
N1 - Funding Information:
A.M.F. reports being on the scientific advisory boards of IBL Interna-tional and Roche, and is a consultant for AbbVie and Novartis. Neither J.C.M. nor his family owns stock or has equity interest (outside of mutual funds or other externally directed accounts) in any pharmaceutical or biotechnology company. J.C.M. is currently par-ticipating in clinical trials of antidementia drugs from Eli Lilly and Company, Biogen, and Janssen. J.C.M. serves as a consultant for Lilly USA. He receives research support from Eli Lilly/Avid Radio-pharmaceuticals and is funded by NIH grants # P50AG005681; P01AG003991; P01AG026276; and UF01AG032438. The remaining authors declare no conflicts of interest.
Funding Information:
Supported by the National Institute on Aging (R01AG043434, R01AG43434-03S1, P50AG005681, P01AG003991, P01AG026276, and K12 HD001459), and the Charles and Joanne Knight Alz-heimer Research Initiative of the Washington University Knight Alzheimer Disease Research Center (ADRC).
Publisher Copyright:
© 2017 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2018
Y1 - 2018
N2 - Purpose: Older adults experience impaired driving performance, and modify their driving habits, including limiting amount and spatial extent of travel. Alzheimer disease (AD)-related pathology, as well as spatial navigation difficulties, may influence driving performance and driving behaviors in clinically normal older adults. We examined whether AD biomarkers [cerebrospinal fluid (CSF) concentrations of Aβ 42, tau, and ptau 181 ] were associated with lower self-reported spatial navigation abilities, and whether navigation abilities mediated the relationship of AD biomarkers with driving performance and extent. Methods: Clinically normal older adults (n=112; aged 65+) completed an on-road driving test, the Santa Barbara Sense of Direction scale (self-report measure of spatial navigation ability), and the Driving Habits Questionnaire for an estimate of driving extent (composite of driving exposure and driving space). All participants had a lumbar puncture to obtain CSF. Results: CSF Aβ 42, but not tau or ptau 181, was associated with self-reported navigation ability. Lower self-reported navigation was associated with reduced driving extent, but not driving errors. Self-reported navigation mediated the relationship between CSF Aβ 42 and driving extent. Conclusions: Findings suggest that cerebral amyloid deposition is associated with lower perceived ability to navigate the environment, which may lead older adults with AD pathology to limit their driving extent.
AB - Purpose: Older adults experience impaired driving performance, and modify their driving habits, including limiting amount and spatial extent of travel. Alzheimer disease (AD)-related pathology, as well as spatial navigation difficulties, may influence driving performance and driving behaviors in clinically normal older adults. We examined whether AD biomarkers [cerebrospinal fluid (CSF) concentrations of Aβ 42, tau, and ptau 181 ] were associated with lower self-reported spatial navigation abilities, and whether navigation abilities mediated the relationship of AD biomarkers with driving performance and extent. Methods: Clinically normal older adults (n=112; aged 65+) completed an on-road driving test, the Santa Barbara Sense of Direction scale (self-report measure of spatial navigation ability), and the Driving Habits Questionnaire for an estimate of driving extent (composite of driving exposure and driving space). All participants had a lumbar puncture to obtain CSF. Results: CSF Aβ 42, but not tau or ptau 181, was associated with self-reported navigation ability. Lower self-reported navigation was associated with reduced driving extent, but not driving errors. Self-reported navigation mediated the relationship between CSF Aβ 42 and driving extent. Conclusions: Findings suggest that cerebral amyloid deposition is associated with lower perceived ability to navigate the environment, which may lead older adults with AD pathology to limit their driving extent.
KW - amyloid deposition
KW - driving space
KW - on-road driving test
KW - preclinical Alzheimer disease
UR - http://www.scopus.com/inward/record.url?scp=85048034937&partnerID=8YFLogxK
U2 - 10.1097/WAD.0000000000000257
DO - 10.1097/WAD.0000000000000257
M3 - Article
C2 - 29578861
AN - SCOPUS:85048034937
VL - 32
SP - 101
EP - 106
JO - Alzheimer Disease and Associated Disorders
JF - Alzheimer Disease and Associated Disorders
SN - 0893-0341
IS - 2
ER -